Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

被引：0
|
作者：
Zeqing Zhang
Xi Chen
Puhan Lu
Jianhua Zhang
Yongping Xu
Wentao He
Mengni Li
Shujun Zhang
Jing Jia
Shiying Shao
Junhui Xie
Yan Yang
Xuefeng Yu
机构：
[1] Huazhong University of Science and Technology,Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Glucagon-like peptide-1 agonists; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Cardiovascular outcomes; Acute pancreatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 31 条
  • [1] Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zhang, Zeqing
    Chen, Xi
    Lu, Puhan
    Zhang, Jianhua
    Xu, Yongping
    He, Wentao
    Li, Mengni
    Zhang, Shujun
    Jia, Jing
    Shao, Shiying
    Xie, Junhui
    Yang, Yan
    Yu, Xuefeng
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [2] Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
    Mann, Johannes F. E.
    Muskiet, Marcel H. A.
    KIDNEY INTERNATIONAL, 2021, 99 (02) : 314 - 318
  • [3] Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Farngren, Johan
    Ahren, Bo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 99 : 25 - 31
  • [4] Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
    Davies, Melanie J.
    Bianchi, Cristina
    Del Prato, Stefano
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 107
  • [5] Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
    Vasiliki Bistola
    Vaia Lambadiari
    George Dimitriadis
    Ioannis Ioannidis
    Konstantinos Makrilakis
    Nikolaos Tentolouris
    Apostolos Tsapas
    John Parissis
    Heart Failure Reviews, 2018, 23 : 377 - 388
  • [6] Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
    Bistola, Vasiliki
    Lambadiari, Vaia
    Dimitriadis, George
    Ioannidis, Ioannis
    Makrilakis, Konstantinos
    Tentolouris, Nikolaos
    Tsapas, Apostolos
    Parissis, John
    HEART FAILURE REVIEWS, 2018, 23 (03) : 377 - 388
  • [7] Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis
    Evans, Marc
    Kuodi, Paul
    Akunna, Chisom Joyqueenet
    Mccreedy, Nicole
    Donsmark, Morten
    Ren, Hongye
    Nnaji, Chukwudi A.
    DIABETES & VASCULAR DISEASE RESEARCH, 2023, 20 (06)
  • [8] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [9] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Liakos, Charalampos I.
    Papadopoulos, Dimitrios P.
    Sanidas, Elias A.
    Markou, Maria I.
    Hatziagelaki, Erifili E.
    Grassos, Charalampos A.
    Velliou, Maria L.
    Barbetseas, John D.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (02) : 123 - 137
  • [10] Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach
    Bronden, Andreas
    Christensen, Mikkel Bring
    Glintborg, Dorte
    Snorgaard, Ole
    Kofoed-Enevoldsen, Allan
    Madsen, Gitte Krogh
    Toft, Katja
    Kristensen, Jette Kolding
    Hojlund, Kurt
    Hansen, Troels Krarup
    Sondergaard, Esben
    Hansen, Katrine Bagge
    DIABETIC MEDICINE, 2023, 40 (08)
1234